Determine opportunities to accelerate the availability of an effective, safe, commercially produced and licensed blood (red cell) substitute to the United States military.

The NRAC Terms of Reference (TOR) that was developed from congressional tasking is as follows:

**GENERAL OBJECTIVE**

To evaluate opportunities to accelerate availability of artificial blood substitute products, (oxygen carrying), through testing, development of manufacturing methods or other developmental support where warranted for military use and other future applications; and to develop a strategy and plan that identifies a development framework, timetable, and investment recommendation for Congress.

**BACKGROUND**

HASC Report 102-60 of 13 May 1991 directed the Secretary of the Navy to provide the report outlined above. “Artificial Blood,” when developed, will have such obviously important and far reaching effects for the military and the world in general as to be compared to the development of blood transfusion technology earlier in this century. A “Sources Sought” announcement has been published in the Commerce Business Daily of 29 August 1991 to assess interest in participating in this process. Eighteen organizations, as well as the Department of Defense and U.S. Army, have expressed interest.
SPECIFIC TASKING

a. Determine the opportunities for acceleration of artificial blood substitute products into the military by evaluating the state of testing, state of manufacturing methods, appropriate accomplishments of non-DoD investments, and developmental support requirements for implementation.

b. Make recommendations for a strategy and plan that consider developmental framework, implementation timetable, and investment strategy for the military.

c. Make all recommendations and assessments necessary to result in an effective, safe, commercially produced, and licensed erythrocyte (oxygen carrying) substitute being made available to the United States military.